title: Role of adjuvant chemotherapy in NSCLC (stages I to III).
abstract: Complete surgical resection is the main therapy for early-stage non-small cell lung cancer. Survival rates remain, at best, 80% for stage IA, necessitating the development of effective systemic therapy. Several large randomized control trials and meta-analyses provide evidence for the use of adjuvant chemotherapy for stage I to III, and are the basis for the standards of care. Cisplatin-based adjuvant chemotherapy regimens have shown 4% to 15% survival advantage at 5 years. Given this modest survival benefit, research is focused on the identification of prognostic and predictive markers to aid in the selection of appropriate adjuvant chemotherapy regimens.
authors: Division of Thoracic surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
authors: Melissa H
authors: MH
authors: Coleman
authors: Raphael
authors: R
authors: Bueno
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents